Information de reference pour ce titreAccession Number: | 00002030-201009100-00002.
|
Author: | Tomescu, Costin a; Duh, Fuh-Mei b; Lanier, Michael A c; Kapalko, Angela d; Mounzer, Karam C d; Martin, Maureen P b; Carrington, Mary b; Metzger, David S c; Montaner, Luis J a
|
Institution: | (a)The Wistar Institute, HIV Immunopathogenesis Laboratory, Philadelphia, Pennsylvania (b)Cancer and Inflammation Program, Laboratory of Experimental Immunology, SAIC-Frederick, Inc., NCI Frederick, Frederick, MD 21702 and Ragon Institute of MGH, MIT and Harvard, Boston, Massachusetts, USA (c)The University of Pennsylvania, Department of Psychiatry, HIV Prevention Division, USA (d)Philadelphia FIGHT, The Jonathan Lax Treatment Center, Philadelphia, Pennsylvania, USA.
|
Title: | |
Source: | AIDS. 24(14):2151-2160, September 10, 2010.
|
Abstract: | Background: Increased natural killer (NK) activation has been associated with resistance to HIV-1 infection in several cohorts of HIV-1 exposed, uninfected individuals. Inheritance of protective NK receptor alleles (KIR3DS1 and KIR3DL1high) has also been observed in a subset of HIV-1 exposed, uninfected individuals. However, the exact mechanism contributing to NK activation in HIV-1 exposed, uninfected intravenous drug users (EU-IDU) remains to be elucidated.
Objective: We investigated the role of both host genotype and pathogen-induced dendritic cell modulation of NK activation during high-risk activity in a cohort of 15 EU-IDU individuals and 15 control, uninfected donors from Philadelphia.
Design: We assessed the activation status of NK cells and dendritic cells by flow cytometry and utilized functional assays of NK-DC cross-talk to characterize the innate immune compartment in EU-IDU individuals.
Results: As previously reported, NK cell activation (CD69) and/or degranulation (CD107a) was significantly increased in EU-IDU individuals compared with control uninfected donors (P = 0.0056, n = 13). Genotypic analysis indicated that the frequency of protective KIR (KIR3DS1) and HLA-Bw4*80I ligands was not enriched in our cohort of EU-IDU individuals. Rather, plasmacytoid dendritic cells (PDC) from EU-IDU exhibited heightened maturation (CD83) compared with control uninfected donors (P = 0.0011, n = 12). When stimulated in vitro, both PDCs and NK cells from EU-IDU individuals maintained strong effector cell function and did not exhibit signs of exhaustion.
Conclusion: Increased maturation of PDCs is associated with heightened NK activation in EU-IDU individuals suggesting that both members of the innate compartment may contribute to resistance from HIV-1 infection in EU-IDU.
Copyright (C) 2010 Wolters Kluwer Health, Inc.
|
Author Keywords: | Exposed/Uninfected; HIV/AIDS; IDU; NK cells; plasmacytoid DC.
|
References: | 1. Muller-Trutwin M, Hosmalin A. Role for plasmacytoid dendritic cells in anti-HIV innate immunity. Immunol Cell Biol 2005; 83:578-583.
2. Smit JJ, Rudd BD, Lukacs NW. Plasmacytoid dendritic cells inhibit pulmonary immunopathology and promote clearance of respiratory syncytial virus. J Exp Med 2006; 203:1153-1159.
3. Yoneyama H, Matsuno K, Toda E, Nishiwaki T, Matsuo N, Nakano A, et al. Plasmacytoid DCs help lymph node DCs to induce anti-HSV CTLs. J Exp Med 2005; 202:425-435.
4. Bandyopadhyay S, Perussia B, Trinchieri G, Miller DS, Starr SE. Requirement for HLA-DR+ accessory cells in natural killing of cytomegalovirus-infected fibroblasts. J Exp Med 1986; 164:180-195.
5. Feldman M, Howell D, Fitzgerald-Bocarsly P. Interferon-alpha-dependent and -independent participation of accessory cells in natural killer cell-mediated lysis of HSV-1-infected fibroblasts. J Leukoc Biol 1992; 52:473-482.
6. Fitzgerald-Bocarsly P, Feldman M, Curl S, Schnell J, Denny T. Positively selected Leu-11a (CD16+) cells require the presence of accessory cells or factors for the lysis of herpes simplex virus-infected fibroblasts but not herpes simplex virus-infected Raji. J Immunol 1989; 143:1318-1326.
7. Oh SH, Bandyopadhyay S, Miller DS, Starr SE. Cooperation between CD16(Leu-11b)+ NK cells and HLA-DR+ cells in natural killing of herpesvirus-infected fibroblasts. J Immunol 1987; 139:2799-2802.
8. Perussia B, Fanning V, Trinchieri G. A leukocyte subset bearing HLA-DR antigens is responsible for in vitro alpha interferon production in response to viruses. Nat Immun Cell Growth Regul 1985; 4:120-137.
9. Tomescu C, Chehimi J, Maino VC, Montaner LJ. NK cell lysis of HIV-1-infected autologous CD4 primary T cells: requirement for IFN-mediated NK activation by plasmacytoid dendritic cells. J Immunol 2007; 179:2097-2104.
10. Biassoni R, Cantoni C, Pende D, Sivori S, Parolini S, Vitale M, et al. Human natural killer cell receptors and co-receptors. Immunol Rev 2001; 181:203-214.
11. Long EO, Burshtyn DN, Clark WP, Peruzzi M, Rajagopalan S, Rojo S, et al. Killer cell inhibitory receptors: diversity, specificity, and function. Immunol Rev 1997; 155:135-144.
12. Boyton RJ, Altmann DM. Natural killer cells, killer immunoglobulin-like receptors and human leucocyte antigen class I in disease. Clin Exp Immunol 2007; 149:1-8.
13. Altfeld M, Kalife ET, Qi Y, Streeck H, Lichterfeld M, Johnston MN, et al. HLA alleles associated with delayed progression to AIDS contribute strongly to the initial CD8+ T cell response against HIV-1. PLoS Med 2006; 3:e403.
14. Martin MP, Qi Y, Gao X, Yamada E, Martin JN, Pereyra F, et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet 2007; 39:733-740.
15. Martin MP, Gao X, Lee JH, Nelson GW, Detels R, Goedert JJ, et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 2002; 31:429-434.
16. Boulet S, Kleyman M, Kim JY, Kamya P, Sharafi S, Simic N, et al. A combined genotype of KIR3DL1 high expressing alleles and HLA-B*57 is associated with a reduced risk of HIV infection. AIDS 2008; 22:1487-1491.
17. Boulet S, Sharafi S, Simic N, Bruneau J, Routy JP, Tsoukas CM, Bernard NF. Increased proportion of KIR3DS1 homozygotes in HIV-exposed uninfected individuals. AIDS 2008; 22:595-599.
18. Boileau C, Bruneau J, Al-Nachawati H, Lamothe F, Vincelette J. A prognostic model for HIV seroconversion among injection drug users as a tool for stratification in clinical trials. J Acquir Immune Defic Syndr 2005; 39:489-495.
19. Scott-Algara D, Truong LX, Versmisse P, David A, Luong TT, Nguyen NV, et al. Cutting edge: increased NK cell activity in HIV-1-exposed but uninfected Vietnamese intravascular drug users. J Immunol 2003; 171:5663-5667.
20. Montoya CJ, Velilla PA, Chougnet C, Landay AL, Rugeles MT. Increased IFN-gamma production by NK and CD3+/CD56+ cells in sexually HIV-1-exposed but uninfected individuals. Clin Immunol 2006: 120:138-146.
21. Tiemessen CT, Shalekoff S, Meddows-Taylor S, Schramm DB, Papathanasopoulos MA, Gray GE, et al. Cutting edge: unusual NK cell responses to HIV-1 peptides are associated with protection against maternal-infant transmission of HIV-1. J Immunol 2009; 182:5914-5918.
22. Hall HI, Song R, Rhodes P, Prejean J, An Q, Lee LM, et al. Estimation of HIV incidence in the United States. JAMA 2008; 300:520-529.
23. Tempalski B, Lieb S, Cleland CM, Cooper H, Brady JE, Friedman SR. HIV prevalence rates among injection drug users in 96 large US metropolitan areas, 1992-2002. J Urban Health 2009; 86:132-154.
24. City of Philadelphia Department of Public Health. Philadelphia integrated epidemiological profile. Edited by Department of Public Health. Philadelphia: Office of HIV Planning; 2009.
25. Williams CT, Metzger DS. Race and distance effects on regular syringe exchange program use and injection risks: a geobehavioral analysis. Am J Public Health 2010; 100:1068-1074.
26. Metraux S, Metzger DS, Culhane DP. Homelessness and HIV risk behaviors among injection drug users. J Urban Health 2004; 81:618-629.
27. Martin MP, Carrington M. KIR locus polymorphisms: genotyping and disease association analysis. Methods Mol Biol 2008; 415:49-64.
28. Ravet S, Scott-Algara D, Bonnet E, Tran HK, Tran T, Nguyen N, et al. Distinctive NK-cell receptor repertoires sustain high-level constitutive NK-cell activation in HIV-exposed uninfected individuals. Blood 2007; 109:4296-4305.
29. Ballan WM, Vu BA, Long BR, Loo CP, Michaelsson J, Barbour JD, et al. Natural killer cells in perinatally HIV-1-infected children exhibit less degranulation compared to HIV-1-exposed uninfected children and their expression of KIR2DL3, NKG2C, and NKp46 correlates with disease severity. J Immunol 2007; 179:3362-3370.
30. Tomescu C, Chehimi J, Maino VC, Montaner LJ. Retention of viability, cytotoxicity, and response to IL-2, IL-15, or IFN-alpha by human NK cells after CD107a degranulation. J Leukoc Biol 2009; 85:871-876.
31. Freeman CM, Martinez FJ, Han MK, Ames TM, Chensue SW, Todt JC, et al. Lung dendritic cell expression of maturation molecules increases with worsening chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180:1179-1188.
32. Vermaelen K, Pauwels R. Pulmonary dendritic cells. Am J Respir Crit Care Med 2005; 172:530-551.
33. Krug A, Rothenfusser S, Hornung V, Jahrsdorfer B, Blackwell S, Ballas ZK, et al. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol 2001; 31:2154-2163.
34. Kerkmann M, Rothenfusser S, Hornung V, Towarowski A, Wagner M, Sarris A, et al. Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells. J Immunol 2003; 170:4465-4474.
35. Schroeder JT, Bieneman AP, Xiao H, Chichester KL, Vasagar K, Saini S, Liu MC. TLR9- and FcepsilonRI-mediated responses oppose one another in plasmacytoid dendritic cells by down-regulating receptor expression. J Immunol 2005; 175:5724-5731.
36. Averill L, Lee WM, Karandikar NJ. Differential dysfunction in dendritic cell subsets during chronic HCV infection. Clin Immunol 2007; 123:40-49.
37. Kanto T, Inoue M, Miyazaki M, Itose I, Miyatake H, Sakakibara M, et al. Impaired function of dendritic cells circulating in patients infected with hepatitis C virus who have persistently normal alanine aminotransferase levels. Intervirology 2006; 49:58-63.
38. Piccioli D, Tavarini S, Nuti S, Colombatto P, Brunetto M, Bonino F, et al. Comparable functions of plasmacytoid and monocyte-derived dendritic cells in chronic hepatitis C patients and healthy donors. J Hepatol 2005; 42:61-67.
39. Wertheimer AM, Bakke A, Rosen HR. Direct enumeration and functional assessment of circulating dendritic cells in patients with liver disease. Hepatology 2004; 40:335-345.
40. Rouveix B. Opiates and immune function. Consequences on infectious diseases with special reference to AIDS. Therapie 1992; 47:503-512.
41. Ugen KE, Nyland SB. Injecting drugs of abuse and immunity: implications for HIV vaccine testing and efficacy. Springer Semin Immunopathol 2006; 28:281-287.
42. Zhang T, Li Y, Ho WZ. Drug abuse, innate immunity and hepatitis C virus. Rev Med Virol 2006; 16:311-327.
43. Weed MR, Carruth LM, Adams RJ, Ator NA, Hienz RD. Morphine withdrawal dramatically reduces lymphocytes in morphine-dependent macaques. J Neuroimmune Pharmacol 2006; 1:250-259.
44. Saurer TB, Carrigan KA, Ijames SG, Lysle DT. Suppression of natural killer cell activity by morphine is mediated by the nucleus accumbens shell. J Neuroimmunol 2006; 173:3-11.
|
Language: | English.
|
Document Type: | BASIC SCIENCE.
|
Journal Subset: | Nursing. Clinical Medicine. Health Professions. Life & Biomedical Sciences.
|
ISSN: | 0269-9370
|
NLM Journal Code: | aid, 8710219
|
DOI Number: | https://dx.doi.org/10.1097/QAD.0...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|